%0 Journal Article
%T Evaluation of Factors Affecting Continuous Performance Test Identical Pairs Version Score of Schizophrenic Patients in a Japanese Clinical Sample
%A Takayoshi Koide
%A Branko Aleksic
%A Tsutomu Kikuchi
%A Masahiro Banno
%A Kunihiro Kohmura
%A Yasunori Adachi
%A Naoko Kawano
%A Tetsuya Iidaka
%A Norio Ozaki
%J Schizophrenia Research and Treatment
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/970131
%X Aim. Cognitive impairment in schizophrenia strongly relates to social outcome and is a good candidate for endophenotypes. When we accurately measure drug efficacy or effects of genes or variants relevant to schizophrenia on cognitive impairment, clinical factors that can affect scores on cognitive tests, such as age and severity of symptoms, should be considered. To elucidate the effect of clinical factors, we conducted multiple regression analysis using scores of the Continuous Performance Test Identical Pairs Version (CPT-IP), which is often used to measure attention/vigilance in schizophrenia. Methods. We conducted the CPT-IP (4-4 digit) and examined clinical information (sex, age, education years, onset age, duration of illness, chlorpromazine-equivalent dose, and Positive and Negative Symptom Scale (PANSS) scores) in 126 schizophrenia patients in Japanese population. Multiple regression analysis was used to evaluate the effect of clinical factors. Results. Age, chlorpromazine-equivalent dose, and PANSS-negative symptom score were associated with mean d¡ä score in patients. These three clinical factors explained about 28% of the variance in mean d¡ä score. Conclusions. As conclusion, CPT-IP score in schizophrenia patients is influenced by age, chlorpromazine-equivalent dose and PANSS negative symptom score. 1. Introduction Schizophrenia is a complex, heritable psychiatric disorder, affecting approximately 1% of the general population. The heritability of schizophrenia is estimated to be 64% [1]. Genes relevant to schizophrenia or variants that may modulate risk for the disease have been identified using both linkage and candidate-based or whole-genome association studies [2¨C5]. A complementary approach examines the genetics of schizophrenia from the neurobiological perspective with neurocognitive endophenotypic markers of putative brain function. The underlying brain dysfunctions (and related endophenotypes) are more stable, trait-like markers that can be used to refine the psychiatric diagnosis. This approach is further motivated by the need to elucidate pathophysiological pathways after candidate variants are established [6]. The Consortium on the Genetics of Schizophrenia is a 7-site collaboration that examines the genetic architecture of quantitative endophenotypes in families with schizophrenia. The authors suggested that the Continuous Performance Test Identical Pairs Version (CPT-IP), Degraded Stimulus Continuous Performance Test (DS-CPT), Verbal Declarative Memory Test, Working Memory Test, and Penn Computerized Neurocognitive Battery are the
%U http://www.hindawi.com/journals/schizort/2012/970131/